SCYNEXIS Announces Positive Results from the Second Interim Analysis of Ongoing Phase 3 FURI Study, Demonstrating Oral Ibrexafungerp's Ability to Treat Severe Fungal Infections in the Hospital Setting
Stock Information for SCYNEXIS Inc.
Loading
Please wait while we load your information from QuoteMedia.